JP6933644B2 - アンドロゲン受容体拮抗薬 - Google Patents

アンドロゲン受容体拮抗薬 Download PDF

Info

Publication number
JP6933644B2
JP6933644B2 JP2018511611A JP2018511611A JP6933644B2 JP 6933644 B2 JP6933644 B2 JP 6933644B2 JP 2018511611 A JP2018511611 A JP 2018511611A JP 2018511611 A JP2018511611 A JP 2018511611A JP 6933644 B2 JP6933644 B2 JP 6933644B2
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
membered
nhc
members
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018511611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534243A (ja
JP2018534243A5 (enExample
Inventor
ジョーンズ，ジェレミー
パル，スマンタ・クマール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2018534243A publication Critical patent/JP2018534243A/ja
Publication of JP2018534243A5 publication Critical patent/JP2018534243A5/ja
Application granted granted Critical
Publication of JP6933644B2 publication Critical patent/JP6933644B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
JP2018511611A 2015-09-04 2016-09-02 アンドロゲン受容体拮抗薬 Expired - Fee Related JP6933644B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214613P 2015-09-04 2015-09-04
US62/214,613 2015-09-04
PCT/US2016/050270 WO2017041040A1 (en) 2015-09-04 2016-09-02 Androgen receptor antagonists

Publications (3)

Publication Number Publication Date
JP2018534243A JP2018534243A (ja) 2018-11-22
JP2018534243A5 JP2018534243A5 (enExample) 2019-12-12
JP6933644B2 true JP6933644B2 (ja) 2021-09-08

Family

ID=58188655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511611A Expired - Fee Related JP6933644B2 (ja) 2015-09-04 2016-09-02 アンドロゲン受容体拮抗薬

Country Status (5)

Country Link
US (1) US10428048B2 (enExample)
EP (1) EP3350167A4 (enExample)
JP (1) JP6933644B2 (enExample)
CN (1) CN108349900A (enExample)
WO (1) WO2017041040A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
WO2019023651A2 (en) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR
AU2018316248A1 (en) * 2017-08-09 2020-01-30 Nangenex Nanotechnology Incorporated Pharmaceutical composition comprising Abiraterone acetate and Darulotamide
CN115701991A (zh) * 2020-04-02 2023-02-14 田纳西大学研究基金会 吡唑基丙酰胺化合物及其用于治疗前列腺癌的用途
CN114685601B (zh) 2020-12-30 2024-10-18 财团法人工业技术研究院 雄性激素受体结合分子及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH509382A (it) 1967-06-23 1971-06-30 Crc Ricerca Chim Metodo per l'ottenimento dei colori pirolchinolici e dei loro sali derivati
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EP1841428A1 (en) * 2005-01-18 2007-10-10 Immusol Incorporated Novel quinolinium salts and derivatives
CN101106992A (zh) * 2005-01-18 2008-01-16 伊姆索公司 新颖的喹啉鎓盐和衍生物
WO2008128100A1 (en) 2007-04-13 2008-10-23 The Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
US8354538B2 (en) 2008-04-24 2013-01-15 The Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
KR102193461B1 (ko) * 2014-04-24 2020-12-21 동아에스티 주식회사 퀴놀린계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제

Also Published As

Publication number Publication date
JP2018534243A (ja) 2018-11-22
CN108349900A (zh) 2018-07-31
WO2017041040A1 (en) 2017-03-09
EP3350167A4 (en) 2019-04-03
EP3350167A1 (en) 2018-07-25
US20180244650A1 (en) 2018-08-30
US10428048B2 (en) 2019-10-01

Similar Documents

Publication Publication Date Title
JP6933644B2 (ja) アンドロゲン受容体拮抗薬
JP7690553B2 (ja) Ｐｃｎａ阻害剤
RU2741596C2 (ru) Соединение мочевины, способ его получения и его медицинское применение
JP6972002B2 (ja) ブルトン型チロシンキナーゼを調節する化合物及び方法
CA3189410A1 (en) Kat6 inhibitor methods and combinations for cancer treatment
AU2024202745A1 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
EP3176160B1 (en) Pyridine-substituted 2-aminopyridine protein kinase inhibitors
CN112457306A (zh) 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US20240245634A1 (en) Pcna inhibitors and egfr inhibitors for cancer treatment
CN113677341B (zh) 双环吡啶组合物及其用于癌症治疗的方法
EP3364976A1 (en) Piperazinyl norbenzomorphan compounds and methods for using the same
JP6853833B2 (ja) エストロゲン受容体調節物質の組合せ
WO2016085825A1 (en) Estrogen receptor modulators
WO2025076290A1 (en) 5-6-5/6-bisaryl compounds as flt3 inhibitors
HK1258793B (en) Pcna inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210812

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210819

R150 Certificate of patent or registration of utility model

Ref document number: 6933644

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees